Aim: To determine the safety and usefulness of a novel anticancer drug, miriplatin, in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.
Patients And Methods: Patients (n=115) who underwent TACE with miriplatin-lipiodol suspension (miriplatin group), and control patients (n=131) who underwent TACE with cisplatin-lipiodol suspension (CDDP group) took part in this study.
Results: The overall incidence of adverse events was significantly lower in the miriplatin group. The percentage of patients attaining treatment effect 4 in both groups was not significantly different. The proportion exhibiting a >50% decrease in positive tumor markers following TACE was significantly greater in the CDDP group for alpha-fetoprotein, but not significantly different for des-gammma-carboxy prothrombin.
Conclusion: Miriplatin-lipiodol suspension was associated with reduced intensity of adverse events and had comparable short-term therapeutic effects to cisplatin-lipiodol suspension, thereby indicating its usefulness in TACE.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model.
PLoS One
September 2020
Department of Radiology, Nippon Medical School, Tokyo, Japan.
Transcatheter arterial chemoembolization (TACE) is a standard treatment for unresectable hepatocellular carcinoma; however, it does not always result in tumor control. Nevertheless, treatment outcome can be improved with monodisperse emulsions of anticancer agents. In this study, the distribution of a monodisperse miriplatin-Lipiodol emulsion in the tumor and its safety were evaluated in ten Japanese white rabbits.
View Article and Find Full Text PDFFeasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
Anticancer Res
June 2017
Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine, Hachioji, Japan
Article Synopsis
- The study aimed to assess the safety and feasibility of repeating transarterial chemoembolization (TACE) using a miriplatin-lipiodol suspension for treating patients with hepatocellular carcinoma (HCC).
- Sixteen patients were analyzed, with the study measuring the total doses of miriplatin, lipiodol, and other materials used, along with any adverse events during their first and last TACE sessions.
- Results showed an average of 3.7 TACE sessions per patient without significant differences in adverse effects between the first and last procedures, concluding that repeated TACE with this method is both safe and feasible for selected patients.
Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma.
Hepatol Res
June 2017
Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
Aim: The effect of transcatheter arterial chemoembolization (TACE) is not necessarily sufficient in patients with multiple hepatocellular carcinoma (HCC). We evaluated the antitumor activity and adverse events of TACE using warmed miriplatin suspension for multiple HCC.
Methods: Seventy patients with multiple HCC received TACE using warmed miriplatin/lipiodol suspension, including patients who were TACE-naïve (group A, n = 5), those undergoing initial TACE after radical therapies (group B, n = 31), and those with a history of repeated TACE (group C, n = 34).
Preparation, Characterization, and Antitumor Activities of Miriplatin-Loaded Liposomes.
J Pharm Sci
January 2016
Pharmaceutics Department, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, PR China. Electronic address:
Because of the insolubility of miriplatin in water, miriplatin and lipiodol suspension is the sole formulation of miriplatin approved in Japan to treat hepatocellular carcinoma by transcatheter arterial chemoembolization. Until now, there have been no reports of other pharmaceutical formulations of miriplatin except miriplatin/lipiodol suspension. In this study, we aimed not only to develop miriplatin-loaded liposomes (lipomiriplatins) which could be administrated systematically for tumors besides hepatocellular carcinoma but also to ascertain whether miriplatin, like its analog of NDDP, was a liposome-dependent antitumor agent.
View Article and Find Full Text PDF[Improvement of the viscosity and the intrahepatic distribution of miriplatin-lipiodol suspension].
Gan To Kagaku Ryoho
November 2014
Faculty of Pharmaceutical Sciences, Kobe Gakuin University.
The effects of warming or emulsification with the water-soluble contrast medium, Iomeron (IOM), on reducing the viscosity of miriplatin-lipiodol (MPT-LPD) suspension were studied. Reduction in the viscosity of MPT-LPD suspension was ob- served upon increasing the temperature. Although the O/W MPT-LPD emulsion with a low ratio of MPT-LPD to IOM reduced the viscosity, the effect was lesser than that achieved with the warming treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!